- QHP Capital has appointed Owen Murray as CEO of the combined Bend Bioscience, CoreRx, and Societal entities.
- Murray brings over 25 years of experience in the pharmaceutical and healthcare sectors.
QHP Capital has announced the appointment of Owen Murray as the new Chief Executive Officer for the recently combined entities of Bend Bioscience, CoreRx, and Societal.
Murray, who most recently served as CEO of Aprecia Pharmaceutical, brings over 25 years of experience within the pharmaceutical and healthcare industries. His career spans early product development to commercialization, with senior roles at Cardinal Health, Lundbeck, Ovation Pharmaceuticals, and Recordati Rare Diseases.
Murray’s academic background includes a B.Sc. in Biochemistry from the University of Wales, Swansea, an MBA from Seton Hall University, and an MS in Healthcare Leadership from Brown University.
Upon his appointment, Murray expressed enthusiasm for his new role, stating, “I am thrilled to join the company and both lead and unite our established Bend, CoreRx, and Societal businesses. Our goal is to offer exceptional service to the global pharmaceutical industry.”
Overview of outsourcing trends 
